Document Detail


Cost-effectiveness of rituximab in follicular lymphoma.
MedLine Citation:
PMID:  23140274     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
In advanced follicular lymphoma, rituximab is currently used with chemotherapy as induction therapy, and as maintenance monotherapy following induction in previously untreated patients and treatment-experienced relapsed/refractory patients. Herein, the authors characterize the clinical effectiveness, safety and cost-effectiveness of rituximab in follicular lymphoma, based on the literature review. Rituximab has a favorable safety profile and has been shown to improve progression-free survival, with some evidence of improvements to overall survival, particularly for relapsed/refractory patients. Rituximab has consistently been found to have a favorable economic profile, with cost per quality-adjusted life year falling within standard thresholds for cost-effectiveness. Challenges in cost-effectiveness analysis include the fact that life expectancy for patients with follicular lymphoma exceeds the period of available follow-up data and that treatment pathways are more complex than the model structures frequently used in oncology models. As data accrue and more complex models are developed, the cost-effectiveness of rituximab can be more accurately assessed.
Authors:
Karissa M Johnston; Corneliu Bolbocean; Joseph Connors; Stuart Peacock
Related Documents :
6663664 - Cancer of the paranasal sinuses with particular reference to maxillary sinus cancer.
3972294 - Squamous carcinoma of the vagina: treatment, complications, and long-term follow-up.
3341274 - Malignant submandibular gland tumors. a review of 91 patients.
24327524 - Pretreatment neutrophil: lymphocyte ratio predicts survival for patients with metastati...
21265984 - High-intensity focused ultrasound as salvage therapy for patients with recurrent prosta...
20705564 - A phase ii trial of docetaxel with bevacizumab as first-line therapy for her2-negative ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-11
Journal Detail:
Title:  Expert review of pharmacoeconomics & outcomes research     Volume:  -     ISSN:  1744-8379     ISO Abbreviation:  Expert Rev Pharmacoecon Outcomes Res     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101132257     Medline TA:  Expert Rev Pharmacoecon Outcomes Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Canadian Centre for Applied Research in Cancer Control (ARCC), Vancouver, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Attention deficit hyperactivity disorder, tic disorder, and allergy: Is there a link? A nationwide p...
Next Document:  Synaptotagmin-like protein 4 and rab8 interact and increase dense granule release in platelets.